3'-R-Spiro[cycloalkyl-1(2), (hetaryl-3(4), 6'-[1,2,4]triazino[2,3-c]quinazoline]-2'(7'H)-2-оnes as a perspective class of compounds with actoprotective activity

Authors

  • O. S. Kolomoets Zaporizhzhia State Medical University, Ukraine,
  • О. Yu. Voskoboynik Zaporizhzhia State Medical University, Ukraine,
  • I. S. Nosulenko Zaporizhzhia State Medical University, Ukraine,
  • O. V. Krivoshey Zaporizhzhia State Medical University, Ukraine,
  • A. I. Avramenko Zaporizhzhia State Medical University, Ukraine,
  • G. G. Berest Zaporizhzhia State Medical University, Ukraine,
  • S. I. Kovalenko Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2017.2.95748

Keywords:

3'-R-spiro[cycloalkyl-1(2), (hetaryl-3(4), 6'-1, 2, 4]triazino[2, 3-c]quinazoline]-2'(7'H)-2-оnes, swimming test, normothermia, actoprotective and antiradical activities

Abstract

Quinazolines and their derivatives are a perspective class of compounds with versatile biological activities. Their representatives are used in medical practice as sleeping, diuretic, antimicrobial and antitumor drugs. Continuing our search of perspective compounds with actprotective activity among azolo-(azino-)[c]quinazoline derivatives it was decided to combine the mentioned above heterocyclic system with carbocyclic or heterocyclic fragments in one molecule. Moreover, an affinity to melanocortin-4, nociceptin (NOP), adenosine, GABA and glutamine receptors among spiropiperidines, spiropiperidinoquinazolines, spiropiperidinotriazoloquinazolines, spiroindolinoquinazolines and others was found and as a rule they exhibit neuroprotective, neurotrophic, anti-inflammatory and other actions.

Aim. The aim of the present work was the primary screening of actoprotective activity among novel 3'-R-spiro [cycloalkyl-1(2), (hetaryl-3(4), 6')-[1,2,4]triazino[2,3-c]quinazoline]-2'(7'H)-2-ones, estimating of antiradical activity as the possible mechanism of actoprotection and the evaluation of perspectivity of further profound researches  for high-active compounds.

Materials and methods. Actprotective activity of perspective and unknown 3´-R-spiro[cycloalkyl-1(2), (hetaryl-3(4), 6´-[1,2,4]triazino[2,3-c]quinazoline]-2´(7´H)-2-ones was studied using the swimming test at the temperature 24–26 °C (normothermia) with additional load (10 % from the weight of experimental animal). The experiment was carried out on white Wistar rats and “Mildronate” was used as a reference drug.

Results and discussion. It was found, that most of the tested compounds being intragastrically administrated increased the duration of experimental animals swimming in dose of 50 mg/kg in conditions of normothermia. Also, we found a number of high active compounds (1.6, 1.11, 1.12, 1.18, 1,19, 1.25), that were superior to the reference drug “Mildronate” by the level of actoprotection on 13.2–47.8 %. It was shown that there is no reliable dependence between actoprotective and antiradical activities among 3´-R-spiro[cycloalkyl-1(2), (hetaryl-3(4), 6´-[1,2,4]triazino[2,3-c]quinazoline]-2´(7´H)-2-ones. The analysis of “structure–activity” correlation showed that critical factors in revealing of high actprotective action is not only the size and nature of spirocycle of position 6, but also a substituent in position 3 of triazino[2,3-c]quinazoline system. The most active compounds 1.6, 1.11, 1.12, 1.18, 1.19 and 1.25 were recommended for further pharmacological studies. 

References

Connolly, D. J., Cusack, D., O’Sullivan, T., & Guiry, P. J. (2005) Synthesis of quinazolinones and quinazolines. Tetrahydron, 61, 10153–10202. http://dx.doi.org/10.1016/j.tet.2005.07.010.

SudhakarBabu, K., Prabhakar, V., Ravindranath, L. K., Latha, J., & Nagamaddaiah, H. K. (2015) Quinazoline Derivatives and its Biological Significance. International Journal of Current Trends in Pharmaceutical Research, 3(5), 997–1010.

Imtiaz, Khan, Aliya, Ibrar, Naeem, Abbas, & Aamer, Saeed (2014) Recent advances in the structural library of functionalized quinazolineand quinazolinone scaffolds: Synthetic approaches and multifarious applications. European Journal of Medicinal Chemistry, 76, 193–244. doi: 10.1016/j.ejmech.2014.02.005.

Ugale, V. G., & Bari, S. B. (2014) Quinazolines: new horizons in anticonvulsant therapy. European Journal of Medical Chemistry, 80, 447–501. doi: 10.1016/j.ejmech.2014.04.072.

Michael, J. P. (2008) Quinoline, quinazoline and acridone alkaloids. Nat Prod Rep., 25(1), 166–187. doi: 10.1039/b612168n.

https://www.drugbank.ca/unearth/q?approved=1&button=&c=_score&d=down&illicit=1&investigational=1&nutraceutical=1&query=quinazolin&searcher=drugs&utf8=%E2%9C%93&vet_approved=1&withdrawn=1

Borchardt, A. J., Beauregard, C., Cook, T., Davis, R. L., Gamache, D. A., & Yanni, J. M. (patentee) (2010) Pat. US 2010/0120741 А. Heterocyclic inhibitors of histamine receptors for the treatment of disease. Kalypsys Inc., Alcon Research Ltd (US); Filed: 10.09.2009; Posted: 13.05.2010.

Stepaniuk, H. І., Toziuk, O. Yu., Kovalenko, S. І., Chornoivan, N. І., Antypenko, L. М., Antypenko, О. М. (patentee) (2013) Patent Ukrayiny №79229 MPK (2013.01) A61K 31/00. 5-R-tio-tetrazolo[1,5-s]khinazoliny, shcho pidvyshchuiut fizychnu vytryvalist orhanizmu [Ukraine Patent № 79229 МПК (2013.01) А61К 31/00. 5-R-thiotetrazolo[1,5-c]quinazolines which increase the physical endurance.]. Bulleten, 7. [in Ukrainian].

Stepaniuk, H. І., Berest, H. H., Marynich, L. I., Chornoivan, N. I., Pashinska, O. S., Saienko, A. V., et al. (patentee) (2011) Patent Ukrayiny №96186 MPK (2006.01) S07D 253/06, S07D 253/10,S07D 253/10,S07D 239/72. Soli (3-R-2-okso-2N-[1,2,4]tryazyno[2,3-s]khinazolin-6-il-sulfanil)alkilkarbonovykh kyslot, shcho proiavliaiut protyishemichnu, nootropnu, protysudomnu ta aktoprotektornu aktyvnist [Ukraine Patent №96186 МПК (2006.01) С07D 253/06, С07D 253/10,С07D 253/10,С07D 239/72. 3-R-2-oxo-2Н-[1,2,4]triazino[2,3-с]quinazolin-6-yl-sulfanyl)alkylcarboxylic acids which reveals antiischemic, nootropic, anticonvulsant an actoprotective activity]. Bulleten, 19. [in Ukrainian].

Tozyuk, E. Yu., & Stepanyuk, G. I. (2014) Porivnialna otsinka vplyvu natriiu 2-(tetrazolo[1,5-s]khinazolin-5-iltio)atsetatu ta bemitylu na protses vidnovlennia fizychnoi pratsezdatnosti shchuriv [Comparative evaluation of sodium 2-(tetrazol[1,5-c]quinazolin-5-ylthio)-acetate and bemityl effects on the recovery process of physical working capacity of rats]. Farmakolohiia ta likarska toksykolohiia, 2(38), 59–63. [in Ukrainian].

Pochelova, E. V., Stepanjuk, G. І., Denysiuk, О. N., & Chornoivan, N. G. (2013) Kharakterystyka aktoprotektornoi dii pokhidnykh (3-R-okso-2N-[1,2,4]tryazyno[2,3-s]khinazolin-6-il)karbonovykh kyslot za riznykh temperaturnykh rezhymiv [Сharacteristics of actoprotective actions of (3-R-oxo-2H-[1,2,4]-triazino- [2,2-c]-quinazolin-6-yl) carboxylic acid derivatives at different temperature conditions]. Farmakolohiia ta likarska toksykolohiia, 3(34), 54–57. [in Ukrainian].

Kolomoets, О. S., Nosulenko, I. S., Voskoboynik, О. Yu., Berest, G. G., Kovalenko, S. I., & Trzhetsinsky, S. D. (2016) Aktoprotektorna aktyvnist 6-monozamishchenykh 3-R-6,7-dyhidro-2H-[1,2,4]tryazyno[2,3-c]khinazolin-2-oniv [Actoprotective activity of 6-monosubstituted 3-R-6,7-dihydro-2H-[1,2,4]triazino-[2,3-c]quinazoline-2-ones]. Current issues in pharmacy and medicine: science and practice, 2(12), 80–82. doi: 10.14739/2409-2932.2016.3.77996. [in Ukrainian].

Kholodniak, S. V., Shabelnyk, K. P., Kovalenko, S. I., Voskoboinik, O. Yu., Bielenichev, I. F., Serheieva, T. Yu., & Okovytyi, S. I. (patentee) (2015) Patent Ukrainy na korysnu model №103314 (UA), MPK 2015.01, A61K 31/00. Zamishcheni 2-alkil-(tsykloalkil-, aralkil-, aryl-, hetaryl-)-6H-spiro[indol-3,5-[1,2,4]tryazolo[1,5-c]khinazolin]-2(1H)-ony, shcho proiavliaiut protysudomnu diiu [Ukraine Patent №103314 (UA), МПК 2015.01, А61К 31/00.Substituted2'-alkyl-(cycloalkyl -, aralkyl-, aryl-, heteryl -)-6'H-spiro[indole]-3,5'-[1,2,4]triazolo[1,5-c]quinazolin]-2(1H)-ones, revealsanticonvulsantactivity, App. 16.06.2015; Pub. 10.12.2015]. Biulleten, 23. [in Ukrainian].

Mustazza, C., Borioni, A., Sestili, I., Sbraccia, M., Rodomonte, A., Ferretti, R., & Del Giudice, M. R. (2006) Synthesis and evaluation as NOP-ligands of some spiro[piperidine-4,2’(1’H)-quinazolin]-4’(3’H)-ones and spiro[piperidine-4,5’(6’H)-[1,2,4]triazolo[1,5-c]quinazolines]. Chem. Pharm. Bull., 54, 611–622. doi: 10.1002/chin.20064515.

Bakshi, R. K., Dellureficio, J. P., Dobbelaar, P. H. et al. (patentee) (2007) Pat. WO 2007/047496 А2. Acylated spiropiperidine derivativesasmelanocortin-4 receptor modulators; MerckCO, INC. (US); Filed: 18.10.2006; Posted: 26.04.2007.

Sharma, V., Kumar, P., & Pathaka, D. (2010) Biological Importance of the Indole Nucleus in Recent Years: A Comprehensive Review. J. Heterocyclic Chem, 47, 491–502. doi: 10.1002/jhet.349.

Pandeya, S. N., Smitha, S., Jyoti, M., & Sridhar, S. K. (2005) Biological activities of isatin and its derivatives. Acta Pharm, 55, 27–46.

Voskoboinik, О. Yu., Kolomoets, О. S., & Kovalenko, S. І. (patentee). (2015) Patent Ukrainy na vynakhid №111245, S07D 253/06, C07D 253/10, C07D 239/72, C07D 2487/04. 6-Mono- ta 6,6-dyzamishcheni 3-R-8-R3-9-R4-10-R5-11-R6-6,7-dyhidro-2H-[1,2,4]tryazyno[2,3-c]khinazolin-2-ony [Ukraine Patent №111245, С07D 253/06, C07D 253/10, C07D 239/72, C07D 2487/04. Mono- and disubstituted 3-R-8-R3-9-R4-10-R5-11-R6-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]quinazolin-2-ones]. Biulleten, 23. [in Ukrainian].

Kozhemiakin, Yu. М., Khromov, О. S., & Filonenko, М. А. (2002) Naukovo-metodychni rekomendatsii z utrymannia laboratornykh tvaryn ta roboty z nymy [Methodical recommendations for keeping and breeding of laboratory animals and working with them]. Кyiv: Avitsenna. [in Ukrainian].

Nakaz Ministerstva okhorony zdorovia «Poriadok provedennia doklinichnoho vyvchennia likarskykh zasobiv ta ekspertyzy materialiv doklinichnoho vyvchennia likarskykh zasobiv» vid 14.12.2009 r. №944 [Rules for conducting of preclinical study of drugs and expertise of material of preclinical study of drugs from December 14, 2009. №944]. [in Ukrainian].

(1986) European convention for the protection of vertebrate animal used for experimental and other scientific purposes. Strasbourg.

Lukyanchuk,V. D., & Simonova, I. V. (2015) Aktoprotektory: farmakolohiia ta farmakoterapiia [Actoprotectors: pharmacology and pharmacotherapy]. Farmakolohiia ta likarska toksykolohiia, 2(43), 14–26. [in Ukrainian].

Kornienko, V. I., Shikova, V. V., Samura, B. A., Romanenko, N. I., & Rak, Т. N. (2012) Vliyanie ammonievykh solej N-(3-metil-7-acetilmetil-ksantinil)-8-N-zameshchennykh piperaziniya na vynoslivost' krys k fizicheskim nagruzkam [Infl uence of ammonium salts of N-(3-methyl-7-acethylmethylxanthinil)-8-N- of piperazine on rats endurance to the physical loadings]. Problemy ekolohichnoi ta medychnoi henetyky i klinichnoi imunolohii, 6, 385–391. [in Ukrainian].

Kedare, S. B., & Singh, R. P. (2011) Genesis and development of DPPH method of antioxidant assay. J Food Sci Technol, 48, 412–422. doi: 10.1007/s13197-011-0251-1.

Sharma, O. P., & Bhat, T. K. (2009) DPPH antioxidant assay revisited. Food Chemistry, 113, 1202–1205. http://dx.doi.org/10.1016/j.foodchem.2008.08.008.

Downloads

How to Cite

1.
Kolomoets OS, Voskoboynik ОY, Nosulenko IS, Krivoshey OV, Avramenko AI, Berest GG, Kovalenko SI. 3’-R-Spiro[cycloalkyl-1(2), (hetaryl-3(4), 6’-[1,2,4]triazino[2,3-c]quinazoline]-2’(7’H)-2-оnes as a perspective class of compounds with actoprotective activity. Zaporozhye medical journal [Internet]. 2017Mar.14 [cited 2024Apr.24];19(2). Available from: http://zmj.zsmu.edu.ua/article/view/95748

Issue

No. 2 (2017): Zaporozhye medical journal

Section

Problems of pharmacy

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)